
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="7196EBE181CDA66307EBE1001A461835.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="curroncol">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Current Oncology">
<meta name="citation_title" content="Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review">
<meta name="citation_author" content="Wenting Lu">
<meta name="citation_author_institution" content="Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)">
<meta name="citation_author" content="Jiayi Sun">
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)">
<meta name="citation_author_institution" content="Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China">
<meta name="citation_author" content="Yawan Jing">
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)">
<meta name="citation_author_institution" content="Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China">
<meta name="citation_author" content="Jing Xu">
<meta name="citation_author_institution" content="Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)">
<meta name="citation_author" content="Chengming Huang">
<meta name="citation_author_institution" content="Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)">
<meta name="citation_author" content="Yi Deng">
<meta name="citation_author_institution" content="Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)">
<meta name="citation_author" content="Panwen Tian">
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)">
<meta name="citation_author_institution" content="Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China">
<meta name="citation_author" content="Yalun Li">
<meta name="citation_author_institution" content="Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)">
<meta name="citation_author_institution" content="Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China">
<meta name="citation_publication_date" content="2025 Mar 28">
<meta name="citation_volume" content="32">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="201">
<meta name="citation_doi" content="10.3390/curroncol32040201">
<meta name="citation_pmid" content="40277759">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/pdf/curroncol-32-00201.pdf">
<meta name="description" content="Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon EGFR mutations show variable responses, and resistance often ...">
<meta name="og:title" content="Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon EGFR mutations show variable responses, and resistance often ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12025375">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/curroncol32040201"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/curroncol-32-00201.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12025375%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12025375/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12025375/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-curroncol.jpg" alt="Current Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Current Oncology" title="Link to Current Oncology" shape="default" href="https://www.mdpi.com/journal/curroncol" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Curr Oncol</button></div>. 2025 Mar 28;32(4):201. doi: <a href="https://doi.org/10.3390/curroncol32040201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/curroncol32040201</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Curr%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Curr%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Curr%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Curr%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <em>EGFR</em> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Wenting Lu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Wenting Lu</span></h3>
<div class="p">
<sup>1</sup>Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenting Lu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Jiayi Sun</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Jiayi Sun</span></h3>
<div class="p">
<sup>2</sup>Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)</div>
<div class="p">
<sup>3</sup>Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiayi Sun</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jing%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yawan Jing</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yawan Jing</span></h3>
<div class="p">
<sup>2</sup>Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)</div>
<div class="p">
<sup>3</sup>Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jing%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yawan Jing</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jing Xu</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jing Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jing Xu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Chengming Huang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Chengming Huang</span></h3>
<div class="p">
<sup>1</sup>Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chengming Huang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deng%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Yi Deng</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Yi Deng</span></h3>
<div class="p">
<sup>1</sup>Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deng%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yi Deng</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tian%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Panwen Tian</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Panwen Tian</span></h3>
<div class="p">
<sup>2</sup>Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)</div>
<div class="p">
<sup>3</sup>Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tian%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Panwen Tian</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Yalun Li</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Yalun Li</span></h3>
<div class="p">
<sup>2</sup>Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)</div>
<div class="p">
<sup>3</sup>Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yalun Li</span></a>
</div>
</div>
<sup>2,</sup><sup>3,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-curroncol-32-00201">
<sup>1</sup>Department of Respiratory and Critical Care Medicine, Integrated Care Management Center, Institute of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610041, China; wentingluscu@163.com (W.L.); 13982172872@163.com (J.X.); hcm1911@163.com (C.H.); dygo6819@outlook.com (Y.D.)</div>
<div id="af2-curroncol-32-00201">
<sup>2</sup>Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China; sunjy0524@163.com (J.S.); 18076991158@163.com (Y.J.); mrascend@163.com (P.T.)</div>
<div id="af3-curroncol-32-00201">
<sup>3</sup>Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu 610041, China</div>
<div class="author-notes p"><div class="fn" id="c1-curroncol-32-00201">
<sup>*</sup><p class="display-inline">Correspondence: <span>liyalun@wchscu.cn</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 11; Revised 2025 Mar 19; Accepted 2025 Mar 27; Collection date 2025 Apr.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12025375  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40277759/" class="usa-link">40277759</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Epidermal growth factor receptor (<em>EGFR</em>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <em>EGFR</em> mutations show variable responses, and resistance often develops. The C797S mutation is a common resistance mechanism after third-generation <em>EGFR</em>-TKI osimertinib therapy, with no standard treatment established. A 37-year-old Chinese woman with advanced NSCLC harboring <em>EGFR</em> G719S/S768I mutations developed an acquired C797S mutation without T790M after second- and third-generation <em>EGFR</em>-TKI therapy. She was treated with a combination of gefitinib and bevacizumab, achieving a partial response, particularly in liver metastases. Her overall survival exceeded 60 months. Gefitinib combined with bevacizumab demonstrates efficacy in managing NSCLC with uncommon <em>EGFR</em> mutations and overcoming acquired C797S resistance. This combination therapy offers a promising treatment strategy for patients with limited options after resistance to second- and third-generation <em>EGFR</em>-TKIs.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> NSCLC, <em>EGFR</em> mutation, <em>EGFR</em>-TKI, osimertinib, gefitinib, bevacizumab</p></section></section><section id="sec1-curroncol-32-00201"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Epidermal growth factor receptor (<em>EGFR</em>) mutations, a common oncogenic driver in non-small-cell lung cancer (NSCLC), can be targeted by <em>EGFR</em> tyrosine kinase inhibitors (TKIs) to improve patient prognosis. The <em>EGFR</em> exon 19 deletion and exon 21 L858R mutations are the most common activating and sensitizing <em>EGFR</em> mutations, accounting for 85–90% of <em>EGFR</em> mutation-positive cases [<a href="#B1-curroncol-32-00201" class="usa-link" aria-describedby="B1-curroncol-32-00201">1</a>]. Additionally, 10–15% of <em>EGFR</em> mutations are uncommon mutations [<a href="#B2-curroncol-32-00201" class="usa-link" aria-describedby="B2-curroncol-32-00201">2</a>], including <em>EGFR</em> 20ins, G719X, S768I, and L861Q. While limited information is available on the efficacy of <em>EGFR</em>-TKIs for these mutations, current clinical data suggest that they are more sensitive to second- and third-generation <em>EGFR</em>-TKIs than to first-generation <em>EGFR</em>-TKIs, excluding <em>EGFR</em> 20ins [<a href="#B3-curroncol-32-00201" class="usa-link" aria-describedby="B3-curroncol-32-00201">3</a>].</p>
<p>However, targeted therapy inevitably leads to acquired resistance. The most significant mechanism of resistance to first- and second-generation <em>EGFR</em>-TKIs is the acquired <em>EGFR</em> exon 20 p.T790M (T790M) [<a href="#B4-curroncol-32-00201" class="usa-link" aria-describedby="B4-curroncol-32-00201">4</a>]. Osimertinib, a third-generation <em>EGFR</em>-TKI, effectively targets the T790M mutation. However, following second-line treatment with osimertinib, 38% of patients developed resistance due to <em>EGFR</em> abnormalities, with the most common being the <em>EGFR</em> C797S mutation [<a href="#B5-curroncol-32-00201" class="usa-link" aria-describedby="B5-curroncol-32-00201">5</a>]. The T790M and C797S mutations in the <em>EGFR</em> gene are classified as either cis or trans based on their allelic relationship. The T790M-trans-C797S mutation responds to combined first- and third-generation <em>EGFR</em>-TKIs, whereas the T790M-cis-C797S mutation is resistant to all generations of <em>EGFR</em>-TKIs [<a href="#B6-curroncol-32-00201" class="usa-link" aria-describedby="B6-curroncol-32-00201">6</a>]. Based on previous research, patients with the C797S mutation may retain some sensitivity to first- or second-generation <em>EGFR</em>-TKI, such as gefitinib and afatinib [<a href="#B7-curroncol-32-00201" class="usa-link" aria-describedby="B7-curroncol-32-00201">7</a>]. The strategy to effectively overcome C797S-based osimertinib resistance involves fourth-generation <em>EGFR</em>-TKIs, most of which are currently in Phase I/II clinical trials. Therefore, there is no standard treatment for NSCLC patients with C797S mutation, particularly for those who develop this mutation without the T790M mutation after first-line therapy.</p>
<p>To date, there have been no reported cases of NSCLC with <em>EGFR</em> G719S/S768I/C797S triple mutations or their treatments. Here, we describe a patient diagnosed with stage IVB lung adenocarcinoma exhibiting uncommon <em>EGFR</em> mutations, G719S/S768I. After the progression of afatinib treatment, osimertinib was administered. Despite the absence of the T790M mutation, the C797S resistance mutation was identified. Ultimately, the combination of gefitinib and bevacizumab resulted in a partial response (PR) in the patient.</p></section><section id="sec2-curroncol-32-00201"><h2 class="pmc_sec_title">2. Case Presentation</h2>
<p>In November 2019, a 37-year-old woman with no history of smoking was diagnosed with left lung adenocarcinoma with hilar mediastinal lymph node, left supraspinal lymph node, and extensive bone metastases (cT4N3M1c, stage IVB). Targetable mutation detection in tumor tissue using next-generation sequencing (NGS) by the GeneseeqPrime™ panel (Nanjing Geneseeq Technology Inc., Nanjing, China) [<a href="#B8-curroncol-32-00201" class="usa-link" aria-describedby="B8-curroncol-32-00201">8</a>] revealed <em>EGFR</em> exon 18 p.G719S mutation and <em>EGFR</em> exon 20 p.S768I mutation. The patient was administered with first-line afatinib (40 mg daily [qd] by mouth [po]) and subsequently developed new brain lesions (October 2020, <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>) after a 10-month period of stability. And the patient was then treated with second-line osimertinib (80 mg daily [qd] by mouth [po]). However, the patient’s brain lesions continued to deteriorate (February 2021, <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>). Due to the effectiveness of the third-generation <em>EGFR</em>-TKI treatment, third-line afatinib was reverted. Both brain and lung lesions remained stable for a duration of eight months. After developing resistance to afatinib, the patient exhibited disease progression in the brain lesions (November 2021, <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>), leading to the fourth-line almonertinib (220 mg daily [qd] by mouth [po]). After three months, the patient’s brain lesions showed increased progression (February 2022, <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>), prompting the initiation of fifth-line afatinib combined with pemetrexed. The patient expressed concerns regarding potential resistance to afatinib and requested a transition to osimertinib. After thorough evaluation and discussion, the clinical team concurred with proceeding with osimertinib as the subsequent line of therapy. The combination therapy resulted in stable disease (SD) and progression-free survival (PFS) of up to 21 months.</p>
<figure class="fig xbox font-sm" id="curroncol-32-00201-f001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12025375_curroncol-32-00201-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad73/12025375/05d43277edbe/curroncol-32-00201-g001.jpg" loading="lazy" height="392" width="727" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/curroncol-32-00201-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>A summary of the patient’s clinical course. The upper panel shows the various treatments the patient received for <em>EGFR</em>-mutated non-small-cell lung cancer as well as the duration of each treatment. Asterisks indicate the time points for the response assessments. Green arrows indicate the primary lesion, while red arrows indicate the metastatic lesions. Genetic testing results for <em>EGFR</em> of the various tissue biopsies are shown below the corresponding CT images with their minor allele frequency. (<strong>A</strong>) Baseline chest CT scan and head MRI at diagnosis in November 2019. (<strong>B</strong>) SD on afitinib treatment in February 2020. (<strong>C</strong>) Lung lesion SD but head lesions PR on afitinib treatment in October 2020. (<strong>D</strong>) Lung lesion SD but head lesions PR on osimertinib treatment in February 2021. (<strong>E</strong>) SD on afitinib treatment in April 2021. (<strong>F</strong>) Lung lesion SD but head lesions PR on afitinib treatment in November 2021. (<strong>G</strong>) Lung lesion SD but head lesions PR on almonertinib in February 2022. (<strong>H</strong>) SD on afitinib treatment in May 2022. (<strong>I</strong>) Liver lesion and head lesion PD on osimertinib combined with pemetrexed treatment in November 2023. (<strong>J</strong>) PR on gefitinib and bevacizumab treatment in January 2024. Abbreviations: PFS, progression-free survival; PC, pemetrexed + cisplatin; SRT, stereotactic radiotherapy; Pem, pemetrexed; NTB, nab-paclitaxel + tirellizumab + bevacizumab; Bev, bevacizumab; SD, stable disease; PD, progressive disease; PR, partial response.</p></figcaption></figure><p>In November 2023, the patient developed multiple metastases in the chest wall, lungs, liver, and brain (<a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>). Subsequently, a biopsy of a mass in the left chest wall confirmed the involvement of lung adenocarcinoma based on the pathological findings. NGS was performed with the patient’s tissue and revealed the retention of <em>EGFR</em> exon 18 p.G719S, <em>EGFR</em> exon 20 p.S768I, and the emergence of <em>EGFR</em> exon 20 p.C797S. Considering that patients may have developed resistance to osimertinib, the treatment was changed to gefitinib (250 mg daily [qd] by mouth [po]) combined with bevacizumab. After two months of treatment, the patient exhibited a significant reduction in the size of lung, brain, and liver metastases compared with their previous dimensions (January 2024, <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>). The lesions continued to show PR in June 2024. During combination therapy, the patient exhibited only grade 1 transaminase elevations, which improved with hepatoprotective treatment. No other adverse reactions, such as rash, proteinuria, or bleeding, were observed during this period. The patient continues to receive the combination therapy of gefitinib and bevacizumab. To date, the patient has achieved an overall survival (OS) of more than 60 months, with sustained clinical benefit and stable disease. The whole clinical course of treatment is shown in <a href="#curroncol-32-00201-f001" class="usa-link">Figure 1</a>. Antitumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) [<a href="#B9-curroncol-32-00201" class="usa-link" aria-describedby="B9-curroncol-32-00201">9</a>].</p></section><section id="sec3-curroncol-32-00201"><h2 class="pmc_sec_title">3. Discussion</h2>
<p>The <em>EGFR</em> T790M mutation alters the affinity of <em>EGFR</em> for ATP, significantly reducing the effectiveness of first- and second-generation <em>EGFR</em>-TKIs in competing for binding [<a href="#B10-curroncol-32-00201" class="usa-link" aria-describedby="B10-curroncol-32-00201">10</a>]. Osimertinib effectively targets both primary activating mutations and T790M resistance mutations [<a href="#B11-curroncol-32-00201" class="usa-link" aria-describedby="B11-curroncol-32-00201">11</a>]. However, resistance inevitably develops during treatment [<a href="#B12-curroncol-32-00201" class="usa-link" aria-describedby="B12-curroncol-32-00201">12</a>]. Common mechanisms of osimertinib resistance include the <em>EGFR</em> C797S mutation, <em>MET</em> amplification, T790M deletion, <em>BRAF</em> mutations, and <em>KRAS</em> mutations [<a href="#B13-curroncol-32-00201" class="usa-link" aria-describedby="B13-curroncol-32-00201">13</a>,<a href="#B14-curroncol-32-00201" class="usa-link" aria-describedby="B14-curroncol-32-00201">14</a>,<a href="#B15-curroncol-32-00201" class="usa-link" aria-describedby="B15-curroncol-32-00201">15</a>]. The <em>EGFR</em> C797S mutation is the primary cause of acquired resistance to osimertinib, often arising after the T790M mutation. Recently, C797S mutations have been documented in a few cases of T790M-negative patients following osimertinib treatment. It is well known that first-generation <em>EGFR</em>-TKIs are ineffective in patients with the T790M mutation. However, their efficacy in patients with C797S-positive and T790M-negative mutations remains uncertain. We summarized previous studies on the clinical outcomes of subsequent treatments in patients who developed C797S resistance mutations following osimertinib therapy [<a href="#B16-curroncol-32-00201" class="usa-link" aria-describedby="B16-curroncol-32-00201">16</a>,<a href="#B17-curroncol-32-00201" class="usa-link" aria-describedby="B17-curroncol-32-00201">17</a>,<a href="#B18-curroncol-32-00201" class="usa-link" aria-describedby="B18-curroncol-32-00201">18</a>,<a href="#B19-curroncol-32-00201" class="usa-link" aria-describedby="B19-curroncol-32-00201">19</a>,<a href="#B20-curroncol-32-00201" class="usa-link" aria-describedby="B20-curroncol-32-00201">20</a>]. In these cases, re-biopsies were performed on lung tissue, pleural effusion, plasma, and cerebrospinal fluid. The characteristics and clinical data of the patients are presented in <a href="#curroncol-32-00201-t001" class="usa-link">Table 1</a>. All patients received osimertinib and exhibited <em>EGFR</em> C797S-positive and T790M-negative resistance mutations. Notably, two patients with lung adenocarcinoma harboring the <em>EGFR</em> 19del and T790M mutations acquired the C797S mutation after failing osimertinib treatment and subsequently achieved partial remission with gefitinib.</p>
<section class="tw xbox font-sm" id="curroncol-32-00201-t001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Clinical characteristics and treatment outcomes of patients with NSCLC with acquired <em>EGFR</em> C797S after osimertinib resistance.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Article</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age/Gender</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Smoking Status</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Histologic Type</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<em>EGFR</em> Mutation</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<em>EGFR</em>-TKI</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response/PFS (m)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Re-Biopsy Specimen</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Mutations</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Second Treatment</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response/PFS (m)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Re-Biopsy Specimen</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Mutations</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Third Treatment</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response/PFS (m)</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chic N 2017 [<a href="#B18-curroncol-32-00201" class="usa-link" aria-describedby="B18-curroncol-32-00201">18</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78/F</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Never</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19Del</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/30</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M- C797S+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/NA</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enrico D 2023 [<a href="#B14-curroncol-32-00201" class="usa-link" aria-describedby="B14-curroncol-32-00201">14</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66/M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Former</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19Del, T790M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/21</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body fluids</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD/8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bronchoscopy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M- C797S+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/4</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goldberg ME 2018 [<a href="#B15-curroncol-32-00201" class="usa-link" aria-describedby="B15-curroncol-32-00201">15</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53/F</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19Del</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M- C797S+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib + Gefitinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD/5</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goldberg ME 2018 [<a href="#B15-curroncol-32-00201" class="usa-link" aria-describedby="B15-curroncol-32-00201">15</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41/M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19Del</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/23</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liquid biopsy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T790M- C797S+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A cMet inhibitor (clinical trial)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Russo A 2023 [<a href="#B16-curroncol-32-00201" class="usa-link" aria-describedby="B16-curroncol-32-00201">16</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46/F</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Never</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L858R</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion biopsy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C797S</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD/2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liquid biopsy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C797S</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Car + Gem </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD/3</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wang M 2021 [<a href="#B17-curroncol-32-00201" class="usa-link" aria-describedby="B17-curroncol-32-00201">17</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48/F</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19Del</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PR/18</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerebrospinal fluid</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C797S</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib + Pem + Cis +Bev</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD/4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C797S</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD/10</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/curroncol-32-00201-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>Abbreviations: NSCLC: non-small-cell lung cancer; <em>EGFR</em>, Epidermal growth factor receptor; <em>EGFR</em>-TKI, Epidermal growth factor receptor tyrosine kinase inhibitors; PFS, progression-free survival; PR, partial response; SD, stable disease; AC: adenocarcinoma; Pem: pemetrexed; Cis: cisplatin; Bev: bevacizumab; Car: carboplatin; Gem: gemcitabine; NA: not applicable.</p></div></div></section><p>Initially, we selected first-line targeted therapy with afatinib based on a pooled analysis of first-line studies showing favorable responses to afatinib in patients with G719X, S768I, and L861Q mutations, with a PFS comparable to that of common <em>EGFR</em> mutations [<a href="#B21-curroncol-32-00201" class="usa-link" aria-describedby="B21-curroncol-32-00201">21</a>,<a href="#B22-curroncol-32-00201" class="usa-link" aria-describedby="B22-curroncol-32-00201">22</a>]. Additionally, Passaro A et al. [<a href="#B23-curroncol-32-00201" class="usa-link" aria-describedby="B23-curroncol-32-00201">23</a>] demonstrated the promising efficacy of afatinib in a cohort of patients with brain metastases or rare <em>EGFR</em> mutations. In our study, the patient experienced therapeutic failure, as indicated by time to failure, after 10 and 8 months of afatinib treatment, consistent with findings from previous studies [<a href="#B21-curroncol-32-00201" class="usa-link" aria-describedby="B21-curroncol-32-00201">21</a>].</p>
<p>The patient in this case did not exhibit T790M mutation after progressing on afatinib treatment. However, the patient developed a C797S mutation during osimertinib treatment. The C797S mutation affects the cysteine residue at position 797 of the <em>EGFR</em> protein, and osimertinib demonstrated a strong antitumor effect by covalently binding to <em>EGFR</em> 797 cysteine [<a href="#B7-curroncol-32-00201" class="usa-link" aria-describedby="B7-curroncol-32-00201">7</a>,<a href="#B24-curroncol-32-00201" class="usa-link" aria-describedby="B24-curroncol-32-00201">24</a>]. Unfortunately, the C797S mutation blocks this binding, leading to further acquired resistance [<a href="#B25-curroncol-32-00201" class="usa-link" aria-describedby="B25-curroncol-32-00201">25</a>]. The case reported by Rangachari et al. [<a href="#B7-curroncol-32-00201" class="usa-link" aria-describedby="B7-curroncol-32-00201">7</a>,<a href="#B26-curroncol-32-00201" class="usa-link" aria-describedby="B26-curroncol-32-00201">26</a>] showed that in the presence of the C797S mutation alone, without T790M, resistant NSCLC patients may still retain sensitivity to gefitinib. The in vitro results presented by Niederst et al. [<a href="#B6-curroncol-32-00201" class="usa-link" aria-describedby="B6-curroncol-32-00201">6</a>] showed that <em>EGFR</em> Del19/C797S-positive and T790M-negative cell lines were resistant to third-generation <em>EGFR</em>-TKIs but remained sensitive to gefitinib. This may be due to the fact that the first-generation <em>EGFR</em>-TKI is primarily a reversible, non-selective inhibitor with a quinoline–amine structural motif that is not dependent on the cysteine at 797 to inhibit <em>EGFR</em> [<a href="#B24-curroncol-32-00201" class="usa-link" aria-describedby="B24-curroncol-32-00201">24</a>]. Consequently, first-generation <em>EGFR</em>-TKIs, such as gefitinib, still exert an inhibitory effect on the C797S mutation.</p>
<p>Studies have demonstrated that following the development of resistance to <em>EGFR</em>-TKIs, the level of tumor vascular endothelial growth factor (VEGF) increases [<a href="#B27-curroncol-32-00201" class="usa-link" aria-describedby="B27-curroncol-32-00201">27</a>], reducing tumor cell dependence on the <em>EGFR</em> signal and increasing dependence on the VEGF pathway. Preclinical studies have shown that an overactive VEGF/VEGFR pathway and tumor angiogenesis play a crucial role in the development of resistance to <em>EGFR</em>-TKIs. Bevacizumab, a monoclonal antibody that inhibits VEGF, has been utilized in various cancers due to its ability to suppress tumor angiogenesis. Studies indicate that bevacizumab can lead to significant improvements in PFS when used as a single agent, particularly in patients who cannot tolerate other chemotherapy options [<a href="#B28-curroncol-32-00201" class="usa-link" aria-describedby="B28-curroncol-32-00201">28</a>].</p>
<p>A previous Phase II clinical study showed that bevacizumab combined with first-generation <em>EGFR</em>-TKI significantly prolonged PFS in patients with NSCLC carrying <em>EGFR</em> mutations [<a href="#B29-curroncol-32-00201" class="usa-link" aria-describedby="B29-curroncol-32-00201">29</a>]. The combination of bevacizumab with an <em>EGFR</em>-TKI may enhance antitumor efficacy by targeting distinct pathogenic pathways, including angiogenesis and <em>EGFR</em> activation [<a href="#B30-curroncol-32-00201" class="usa-link" aria-describedby="B30-curroncol-32-00201">30</a>]. Additionally, in cases of tertiary C797S mutation, reintroducing a first-generation <em>EGFR</em>-TKI can still target the original sensitive <em>EGFR</em> mutation, even in the absence of T790M [<a href="#B16-curroncol-32-00201" class="usa-link" aria-describedby="B16-curroncol-32-00201">16</a>]. Thus, the dual targeting of the VEGF and EGFR pathways may effectively prevent drug resistance [<a href="#B31-curroncol-32-00201" class="usa-link" aria-describedby="B31-curroncol-32-00201">31</a>]. This is evidenced by our clinical case, which demonstrated the effectiveness of combining gefitinib, a first-generation <em>EGFR</em>-TKI, with bevacizumab in treating the <em>EGFR</em> C797S mutation following progression on the third-generation <em>EGFR</em>-TKI osimertinib.</p>
<p>Although gefitinib is typically well tolerated, it is associated with several adverse effects, including rash, diarrhea, and liver function abnormalities [<a href="#B32-curroncol-32-00201" class="usa-link" aria-describedby="B32-curroncol-32-00201">32</a>]. In addition, bevacizumab may lead to potential complications such as hypertension, bleeding, and gastrointestinal perforation [<a href="#B33-curroncol-32-00201" class="usa-link" aria-describedby="B33-curroncol-32-00201">33</a>]. The concomitant use of these two agents could increase the incidence of adverse events. Nevertheless, data from a Phase II clinical trial conducted in Japan indicated that serious adverse events associated with the combination of gefitinib and bevacizumab included grade 3 rash, hypertension, elevated aspartate aminotransferase and alanine aminotransferase, proteinuria, intracranial bleeding, and grade 4 gastrointestinal perforation [<a href="#B34-curroncol-32-00201" class="usa-link" aria-describedby="B34-curroncol-32-00201">34</a>]. Notably, no treatment-related deaths were reported. Fortunately, the patient in this case did not experience any of the serious adverse reactions, but close monitoring is still necessary during the combination therapy.</p>
<p>The <em>EGFR</em> C797S mutation is a key driver of resistance to third-generation <em>EGFR</em>-TKIs, making the development of next-generation inhibitors crucial for NSCLC treatment. Several fourth-generation <em>EGFR</em>-TKIs are currently in clinical trials. Although BLU-945 was one of the most advanced fourth-generation <em>EGFR</em>-TKIs [<a href="#B35-curroncol-32-00201" class="usa-link" aria-describedby="B35-curroncol-32-00201">35</a>,<a href="#B36-curroncol-32-00201" class="usa-link" aria-describedby="B36-curroncol-32-00201">36</a>], it was discontinued due to its dose-limiting toxicity and limited clinical benefit. EAI045, which targets the <em>EGFR</em> activator subunit, has proven ineffective as a monotherapy in blocking <em>EGFR</em>-driven cell proliferation, though it demonstrates significant antitumor activity in vitro and in animal models when combined with cetuximab [<a href="#B37-curroncol-32-00201" class="usa-link" aria-describedby="B37-curroncol-32-00201">37</a>,<a href="#B38-curroncol-32-00201" class="usa-link" aria-describedby="B38-curroncol-32-00201">38</a>]. Additionally, BDTX-1535, an orally bioavailable, potent, selective, and irreversible allosteric <em>EGFR</em> inhibitor, has shown promising preliminary efficacy and durability in Phase II trials in patients with relapsed or refractory <em>EGFR</em>-mutant NSCLC [<a href="#B39-curroncol-32-00201" class="usa-link" aria-describedby="B39-curroncol-32-00201">39</a>,<a href="#B40-curroncol-32-00201" class="usa-link" aria-describedby="B40-curroncol-32-00201">40</a>]. These agents offer novel therapeutic options with the potential to overcome resistance to third-generation <em>EGFR</em>-TKIs in NSCLC and other lung cancers.</p>
<p>For patients who develop a C797S mutation without a concurrent T790M mutation following treatment with <em>EGFR</em>-TKIs, the range of effective therapeutic options remains limited. In this case, while the patient exhibited PR to the combination of gefitinib and bevacizumab, the assessment of efficacy and the duration of treatment were relatively brief. It is therefore not possible to ascertain with certainty the precise efficacy of this combination therapy. Further studies with extended follow-up periods, along with overall survival and quality of life data, are required to evaluate the potential of this combination therapy in such cases.</p></section><section id="sec4-curroncol-32-00201"><h2 class="pmc_sec_title">4. Conclusions</h2>
<p>In summary, we reported the clinical benefit of gefitinib combined with bevacizumab in a case characterized by <em>EGFR</em> G719S and S768I mutations/T790M negativity/C797S mutation-mediated resistance to osimertinib. Currently, treatment options for osimertinib-induced C797S mutation resistance are limited. This combination treatment may offer a potential new strategy.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors kindly thank the physicians, nurses, and other staff at the hospital who assisted with the study.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<p>The following abbreviations are used in this manuscript:
</p>
<section class="tw xbox font-sm" id="array1"><div class="tbl-box p" tabindex="0"><table class="content">
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">EGFR</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">EGFR-TKIs</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor tyrosine kinase inhibitors</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Non-small-cell lung cancer</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PR</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Partial response</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">NGS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Next-generation sequencing</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">SD</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Stable disease</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PFS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Progression-free survival</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">OS</td>
<td align="left" valign="top" rowspan="1" colspan="1">Overall survival</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">VEGF</td>
<td align="left" valign="top" rowspan="1" colspan="1">Vascular endothelial growth factor</td>
</tr>
</table></div>
<div class="p text-right font-secondary"><a href="table/array1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, W.L. and Y.L.; methodology, W.L., P.T. and Y.L.; software, W.L.; validation, P.T. and Y.L.; formal analysis, W.L., P.T. and Y.L.; investigation, W, L., J.S., Y.J., J.X., C.H. and Y.D.; resources, P.T. and Y.L.; data curation, W.L., J.S., Y.J., J.X., C.H. and Y.D.; writing—original draft preparation, W.L. and Y.L.; writing—review and editing, W.L., J.S., Y.J., J.X., C.H., Y.D., P.T. and Y.L.; visualization, W.L. and Y.L.; supervision, P.T. and Y.L.; project administration, W.L., P.T. and Y.L.; funding acquisition, P.T. and Y.L. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Institutional Review Board Statement</h2>
<p>This study was conducted in accordance with the principles of the Declaration of Helsinki, and the patient provided written informed consent. IRB approval is not required at our institution for case-report studies.</p></section><section id="notes3"><h2 class="pmc_sec_title">Informed Consent Statement</h2>
<p>Written informed consent was obtained from the patient for the anonymized information and the accompanying images to be published in this article.</p></section><section id="notes4"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>All data underlying the findings of this study are available within this publication. Patient data from the West China Hospital in Sichuan University have been anonymized to ensure confidentiality. Due to ethical and legal restrictions related to data protection regulations, raw patient data cannot be shared publicly. Requests for further information may be directed to the corresponding author.</p></section><section id="notes5"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This work was supported by the National Natural Science Foundation of China (82470099 to Y Li, No. 82473213 to P Tian, 92159302 to W Li), Noncommunicable Chronic Diseases-National Science and Technology Major Project (No. 2024ZD0522806/2024ZD0522800 to P Tian, 2024ZD0522801 to Y Li, 2024ZD0522806 to W Lu).</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Disclaimer/Publisher’s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-curroncol-32-00201">
<span class="label">1.</span><cite>He Q., Qu M., Bao H., Xu Y., Shen T., Tan D., Barkat M.Q., Xu C., Zeng L.H., Wu X. Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations. Cytokine Growth Factor Rev. 2023;70:41–53. doi: 10.1016/j.cytogfr.2023.03.003.</cite> [<a href="https://doi.org/10.1016/j.cytogfr.2023.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36934069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine%20Growth%20Factor%20Rev.&amp;title=Multiple%20post-translational%20modifications%20ensure%20EGFR%20functionality:%20Potential%20therapeutic%20targets%20to%20overcome%20its%20drug-resistance%20mutations&amp;author=Q.%20He&amp;author=M.%20Qu&amp;author=H.%20Bao&amp;author=Y.%20Xu&amp;author=T.%20Shen&amp;volume=70&amp;publication_year=2023&amp;pages=41-53&amp;pmid=36934069&amp;doi=10.1016/j.cytogfr.2023.03.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-curroncol-32-00201">
<span class="label">2.</span><cite>Kobayashi Y., Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179–1186. doi: 10.1111/cas.12996.</cite> [<a href="https://doi.org/10.1111/cas.12996" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5021039/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27323238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci.&amp;title=Not%20all%20epidermal%20growth%20factor%20receptor%20mutations%20in%20lung%20cancer%20are%20created%20equal:%20Perspectives%20for%20individualized%20treatment%20strategy&amp;author=Y.%20Kobayashi&amp;author=T.%20Mitsudomi&amp;volume=107&amp;publication_year=2016&amp;pages=1179-1186&amp;pmid=27323238&amp;doi=10.1111/cas.12996&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-curroncol-32-00201">
<span class="label">3.</span><cite>Borgeaud M., Parikh K., Banna G.L., Kim F., Olivier T., Le X., Addeo A. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. J. Thorac. Oncol. 2024;19:973–983. doi: 10.1016/j.jtho.2024.03.016.</cite> [<a href="https://doi.org/10.1016/j.jtho.2024.03.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38499147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Unveiling%20the%20Landscape%20of%20Uncommon%20EGFR%20Mutations%20in%20NSCLC-A%20Systematic%20Review&amp;author=M.%20Borgeaud&amp;author=K.%20Parikh&amp;author=G.L.%20Banna&amp;author=F.%20Kim&amp;author=T.%20Olivier&amp;volume=19&amp;publication_year=2024&amp;pages=973-983&amp;pmid=38499147&amp;doi=10.1016/j.jtho.2024.03.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-curroncol-32-00201">
<span class="label">4.</span><cite>Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013;19:2240–2247. doi: 10.1158/1078-0432.CCR-12-2246.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-12-2246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3630270/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23470965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Analysis%20of%20tumor%20specimens%20at%20the%20time%20of%20acquired%20resistance%20to%20EGFR-TKI%20therapy%20in%20155%20patients%20with%20EGFR-mutant%20lung%20cancers&amp;author=H.A.%20Yu&amp;author=M.E.%20Arcila&amp;author=N.%20Rekhtman&amp;author=C.S.%20Sima&amp;author=M.F.%20Zakowski&amp;volume=19&amp;publication_year=2013&amp;pages=2240-2247&amp;pmid=23470965&amp;doi=10.1158/1078-0432.CCR-12-2246&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-curroncol-32-00201">
<span class="label">5.</span><cite>Schoenfeld A.J., Chan J.M., Kubota D., Sato H., Rizvi H., Daneshbod Y., Chang J.C., Paik P.K., Offin M., Arcila M.E., et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clin. Cancer Res. 2020;26:2654–2663. doi: 10.1158/1078-0432.CCR-19-3563.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-3563" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7448565/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31911548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Tumor%20Analyses%20Reveal%20Squamous%20Transformation%20and%20Off-Target%20Alterations%20As%20Early%20Resistance%20Mechanisms%20to%20First-line%20Osimertinib%20in%20EGFR-Mutant%20Lung%20Cancer&amp;author=A.J.%20Schoenfeld&amp;author=J.M.%20Chan&amp;author=D.%20Kubota&amp;author=H.%20Sato&amp;author=H.%20Rizvi&amp;volume=26&amp;publication_year=2020&amp;pages=2654-2663&amp;pmid=31911548&amp;doi=10.1158/1078-0432.CCR-19-3563&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-curroncol-32-00201">
<span class="label">6.</span><cite>Niederst M.J., Hu H., Mulvey H.E., Lockerman E.L., Garcia A.R., Piotrowska Z., Sequist L.V., Engelman J.A. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin. Cancer Res. 2015;21:3924–3933. doi: 10.1158/1078-0432.CCR-15-0560.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-0560" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4587765/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25964297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=The%20Allelic%20Context%20of%20the%20C797S%20Mutation%20Acquired%20upon%20Treatment%20with%20Third-Generation%20EGFR%20Inhibitors%20Impacts%20Sensitivity%20to%20Subsequent%20Treatment%20Strategies&amp;author=M.J.%20Niederst&amp;author=H.%20Hu&amp;author=H.E.%20Mulvey&amp;author=E.L.%20Lockerman&amp;author=A.R.%20Garcia&amp;volume=21&amp;publication_year=2015&amp;pages=3924-3933&amp;pmid=25964297&amp;doi=10.1158/1078-0432.CCR-15-0560&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-curroncol-32-00201">
<span class="label">7.</span><cite>Ercan D., Choi H.G., Yun C.H., Capelletti M., Xie T., Eck M.J., Gray N.S., Jänne P.A. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin. Cancer Res. 2015;21:3913–3923. doi: 10.1158/1078-0432.CCR-14-2789.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-14-2789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4791951/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25948633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=EGFR%20Mutations%20and%20Resistance%20to%20Irreversible%20Pyrimidine-Based%20EGFR%20Inhibitors&amp;author=D.%20Ercan&amp;author=H.G.%20Choi&amp;author=C.H.%20Yun&amp;author=M.%20Capelletti&amp;author=T.%20Xie&amp;volume=21&amp;publication_year=2015&amp;pages=3913-3923&amp;pmid=25948633&amp;doi=10.1158/1078-0432.CCR-14-2789&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-curroncol-32-00201">
<span class="label">8.</span><cite>Zheng Q., Lin X., Qi W., Yin J., Li J., Wang Y., Wang W., Li W., Liang Z. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China. Lung Cancer. 2024;194:107897. doi: 10.1016/j.lungcan.2024.107897.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2024.107897" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39068705/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=NGS%20and%20FISH%20for%20MET%20amplification%20detection%20in%20EGFR%20TKI%20resistant%20non-small%20cell%20lung%20cancer%20(NSCLC)%20patients:%20A%20prospective,%20multicenter%20study%20in%20China&amp;author=Q.%20Zheng&amp;author=X.%20Lin&amp;author=W.%20Qi&amp;author=J.%20Yin&amp;author=J.%20Li&amp;volume=194&amp;publication_year=2024&amp;pages=107897&amp;pmid=39068705&amp;doi=10.1016/j.lungcan.2024.107897&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-curroncol-32-00201">
<span class="label">9.</span><cite>Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., et al.  New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur. J. Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.</cite> [<a href="https://doi.org/10.1016/j.ejca.2008.10.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Cancer&amp;title=New%20response%20evaluation%20criteria%20in%20solid%20tumours:%20Revised%20RECIST%20guideline%20(version%201.1)&amp;author=E.A.%20Eisenhauer&amp;author=P.%20Therasse&amp;author=J.%20Bogaerts&amp;author=L.H.%20Schwartz&amp;author=D.%20Sargent&amp;volume=45&amp;publication_year=2009&amp;pages=228-247&amp;pmid=19097774&amp;doi=10.1016/j.ejca.2008.10.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-curroncol-32-00201">
<span class="label">10.</span><cite>Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.  doi: 10.1371/journal.pmed.0020073.</cite> [<a href="https://doi.org/10.1371/journal.pmed.0020073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC549606/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15737014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Med.&amp;title=Acquired%20resistance%20of%20lung%20adenocarcinomas%20to%20gefitinib%20or%20erlotinib%20is%20associated%20with%20a%20second%20mutation%20in%20the%20EGFR%20kinase%20domain&amp;author=W.%20Pao&amp;author=V.A.%20Miller&amp;author=K.A.%20Politi&amp;author=G.J.%20Riely&amp;author=R.%20Somwar&amp;volume=2&amp;publication_year=2005&amp;pages=e73&amp;pmid=15737014&amp;doi=10.1371/journal.pmed.0020073&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-curroncol-32-00201">
<span class="label">11.</span><cite>Remon J., Steuer C.E., Ramalingam S.S., Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann. Oncol. 2018;29((Suppl. S1)):i20–i27. doi: 10.1093/annonc/mdx704.</cite> [<a href="https://doi.org/10.1093/annonc/mdx704" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29462255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Osimertinib%20and%20other%20third-generation%20EGFR%20TKI%20in%20EGFR-mutant%20NSCLC%20patients&amp;author=J.%20Remon&amp;author=C.E.%20Steuer&amp;author=S.S.%20Ramalingam&amp;author=E.%20Felip&amp;volume=29&amp;issue=(Suppl.%20S1)&amp;publication_year=2018&amp;pages=i20-i27&amp;pmid=29462255&amp;doi=10.1093/annonc/mdx704&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-curroncol-32-00201">
<span class="label">12.</span><cite>Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.C., Majem M., Shah R., Rukazenkov Y., et al.  Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat. Commun. 2023;14:1070. doi: 10.1038/s41467-023-35961-y.</cite> [<a href="https://doi.org/10.1038/s41467-023-35961-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9971254/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36849494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Candidate%20mechanisms%20of%20acquired%20resistance%20to%20first-line%20osimertinib%20in%20EGFR-mutated%20advanced%20non-small%20cell%20lung%20cancer&amp;author=J.%20Chmielecki&amp;author=J.E.%20Gray&amp;author=Y.%20Cheng&amp;author=Y.%20Ohe&amp;author=F.%20Imamura&amp;volume=14&amp;publication_year=2023&amp;pages=1070&amp;pmid=36849494&amp;doi=10.1038/s41467-023-35961-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-curroncol-32-00201">
<span class="label">13.</span><cite>Ho C.C., Liao W.Y., Lin C.A., Shih J.Y., Yu C.J., Yang J.C. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J. Thorac. Oncol. 2017;12:567–572. doi: 10.1016/j.jtho.2016.11.2231.</cite> [<a href="https://doi.org/10.1016/j.jtho.2016.11.2231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27923714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Acquired%20BRAF%20V600E%20Mutation%20as%20Resistant%20Mechanism%20after%20Treatment%20with%20Osimertinib&amp;author=C.C.%20Ho&amp;author=W.Y.%20Liao&amp;author=C.A.%20Lin&amp;author=J.Y.%20Shih&amp;author=C.J.%20Yu&amp;volume=12&amp;publication_year=2017&amp;pages=567-572&amp;pmid=27923714&amp;doi=10.1016/j.jtho.2016.11.2231&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-curroncol-32-00201">
<span class="label">14.</span><cite>Ortiz-Cuaran S., Scheffler M., Plenker D., Dahmen L., Scheel A.H., Fernandez-Cuesta L., Meder L., Lovly C.M., Persigehl T., Merkelbach-Bruse S., et al.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin. Cancer Res. 2016;22:4837–4847. doi: 10.1158/1078-0432.CCR-15-1915.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-1915" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27252416/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Heterogeneous%20Mechanisms%20of%20Primary%20and%20Acquired%20Resistance%20to%20Third-Generation%20EGFR%20Inhibitors&amp;author=S.%20Ortiz-Cuaran&amp;author=M.%20Scheffler&amp;author=D.%20Plenker&amp;author=L.%20Dahmen&amp;author=A.H.%20Scheel&amp;volume=22&amp;publication_year=2016&amp;pages=4837-4847&amp;pmid=27252416&amp;doi=10.1158/1078-0432.CCR-15-1915&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-curroncol-32-00201">
<span class="label">15.</span><cite>Yu H.A., Tian S.Z.K., Drilon A.E., Borsu L., Riely G.J., Arcila M.E., Ladanyi M. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol. 2015;1:981–983. doi: 10.1001/jamaoncol.2015.1066.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2015.1066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4665629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26181354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Acquired%20Resistance%20of%20EGFR-Mutant%20Lung%20Cancer%20to%20a%20T790M-Specific%20EGFR%20Inhibitor:%20Emergence%20of%20a%20Third%20Mutation%20(C797S)%20in%20the%20EGFR%20Tyrosine%20Kinase%20Domain&amp;author=H.A.%20Yu&amp;author=S.Z.K.%20Tian&amp;author=A.E.%20Drilon&amp;author=L.%20Borsu&amp;author=G.J.%20Riely&amp;volume=1&amp;publication_year=2015&amp;pages=981-983&amp;pmid=26181354&amp;doi=10.1001/jamaoncol.2015.1066&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-curroncol-32-00201">
<span class="label">16.</span><cite>Enrico D., Tsou F., Catani G., Pupareli C., Girotti M.R., Ulloa Alvarez D.E., Waisberg F., Rodríguez A., Reyes R., Chacón M., et al.  Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report. JTO Clin. Res. Rep. 2023;4:100456. doi: 10.1016/j.jtocrr.2022.100456.</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2022.100456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9926104/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36798785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JTO%20Clin.%20Res.%20Rep.&amp;title=Overcoming%20Resistance%20to%20Osimertinib%20by%20T790M%20Loss%20and%20C797S%20Acquisition%20Using%20Gefitinib%20in%20a%20Patient%20With%20EGFR-Mutant%20NSCLC:%20A%20Case%20Report&amp;author=D.%20Enrico&amp;author=F.%20Tsou&amp;author=G.%20Catani&amp;author=C.%20Pupareli&amp;author=M.R.%20Girotti&amp;volume=4&amp;publication_year=2023&amp;pages=100456&amp;pmid=36798785&amp;doi=10.1016/j.jtocrr.2022.100456&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-curroncol-32-00201">
<span class="label">17.</span><cite>Goldberg M.E., Montesion M., Young L., Suh J., Greenbowe J., Kennedy M., Giaccone G., Akerley W.L., Dowlati A., Creelan B.C., et al.  Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE. 2018;13:e0208097.  doi: 10.1371/journal.pone.0208097.</cite> [<a href="https://doi.org/10.1371/journal.pone.0208097" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6258560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30481207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Multiple%20configurations%20of%20EGFR%20exon%2020%20resistance%20mutations%20after%20first-%20and%20third-generation%20EGFR%20TKI%20treatment%20affect%20treatment%20options%20in%20NSCLC&amp;author=M.E.%20Goldberg&amp;author=M.%20Montesion&amp;author=L.%20Young&amp;author=J.%20Suh&amp;author=J.%20Greenbowe&amp;volume=13&amp;publication_year=2018&amp;pages=e0208097&amp;pmid=30481207&amp;doi=10.1371/journal.pone.0208097&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-curroncol-32-00201">
<span class="label">18.</span><cite>Russo A., Scilla K.A., Mehra R., Gittens A., McCusker M.G., de Miguel-Perez D., Gomez J.E., Peleg A., Del Re M., Rolfo C.D. Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation. Clin. Lung Cancer. 2023;24:660–665. doi: 10.1016/j.cllc.2023.07.003.</cite> [<a href="https://doi.org/10.1016/j.cllc.2023.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37487787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Tracking%20Clonal%20Evolution%20of%20EGFR-Mutated%20Non-Small%20Cell%20Lung%20Cancer%20Through%20Liquid%20Biopsy:%20Management%20of%20C797S%20Acquired%20Mutation&amp;author=A.%20Russo&amp;author=K.A.%20Scilla&amp;author=R.%20Mehra&amp;author=A.%20Gittens&amp;author=M.G.%20McCusker&amp;volume=24&amp;publication_year=2023&amp;pages=660-665&amp;pmid=37487787&amp;doi=10.1016/j.cllc.2023.07.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-curroncol-32-00201">
<span class="label">19.</span><cite>Wang M., Zhu F., Luo N., Li M., Qi Y., Wang M. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report. Medicine. 2021;100:e27727. doi: 10.1097/MD.0000000000027727.</cite> [<a href="https://doi.org/10.1097/MD.0000000000027727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8568434/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34871271/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Erlotinib%20combined%20with%20bevacizumab%20and%20chemotherapy%20in%20first%20line%20osimertinib-resistant%20NSCLC%20patient%20with%20leptomeningeal%20metastasis:%20A%20case%20report&amp;author=M.%20Wang&amp;author=F.%20Zhu&amp;author=N.%20Luo&amp;author=M.%20Li&amp;author=Y.%20Qi&amp;volume=100&amp;publication_year=2021&amp;pages=e27727&amp;pmid=34871271&amp;doi=10.1097/MD.0000000000027727&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-curroncol-32-00201">
<span class="label">20.</span><cite>Chic N., Mayo-de-Las-Casas C., Reguart N. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib. J. Thorac. Oncol. 2017;12:e78–e80. doi: 10.1016/j.jtho.2017.02.014.</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28532569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Successful%20Treatment%20with%20Gefitinib%20in%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20after%20Acquired%20Resistance%20to%20Osimertinib&amp;author=N.%20Chic&amp;author=C.%20Mayo-de-Las-Casas&amp;author=N.%20Reguart&amp;volume=12&amp;publication_year=2017&amp;pages=e78-e80&amp;pmid=28532569&amp;doi=10.1016/j.jtho.2017.02.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-curroncol-32-00201">
<span class="label">21.</span><cite>Yang J.C., Schuler M., Popat S., Miura S., Heeke S., Park K., Märten A., Kim E.S. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J. Thorac. Oncol. 2020;15:803–815. doi: 10.1016/j.jtho.2019.12.126.</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.12.126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31931137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Afatinib%20for%20the%20Treatment%20of%20NSCLC%20Harboring%20Uncommon%20EGFR%20Mutations:%20A%20Database%20of%20693%20Cases&amp;author=J.C.%20Yang&amp;author=M.%20Schuler&amp;author=S.%20Popat&amp;author=S.%20Miura&amp;author=S.%20Heeke&amp;volume=15&amp;publication_year=2020&amp;pages=803-815&amp;pmid=31931137&amp;doi=10.1016/j.jtho.2019.12.126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-curroncol-32-00201">
<span class="label">22.</span><cite>Yang J.C., Sequist L.V., Geater S.L., Tsai C.M., Mok T.S., Schuler M., Yamamoto N., Yu C.J., Ou S.H., Zhou C., et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830–838. doi: 10.1016/S1470-2045(15)00026-1.</cite> [<a href="https://doi.org/10.1016/S1470-2045(15)00026-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26051236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=Clinical%20activity%20of%20afatinib%20in%20patients%20with%20advanced%20non-small-cell%20lung%20cancer%20harbouring%20uncommon%20EGFR%20mutations:%20A%20combined%20post-hoc%20analysis%20of%20LUX-Lung%202,%20LUX-Lung%203,%20and%20LUX-Lung%206&amp;author=J.C.%20Yang&amp;author=L.V.%20Sequist&amp;author=S.L.%20Geater&amp;author=C.M.%20Tsai&amp;author=T.S.%20Mok&amp;volume=16&amp;publication_year=2015&amp;pages=830-838&amp;pmid=26051236&amp;doi=10.1016/S1470-2045(15)00026-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-curroncol-32-00201">
<span class="label">23.</span><cite>Passaro A., de Marinis F., Tu H.Y., Laktionov K.K., Feng J., Poltoratskiy A., Zhao J., Tan E.H., Gottfried M., Lee V., et al.  Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Front. Oncol. 2021;11:709877.  doi: 10.3389/fonc.2021.709877.</cite> [<a href="https://doi.org/10.3389/fonc.2021.709877" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8298067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34307179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Afatinib%20in%20EGFR%20TKI-Na%C3%AFve%20Patients%20with%20Locally%20Advanced%20or%20Metastatic%20EGFR%20Mutation-Positive%20Non-Small%20Cell%20Lung%20Cancer:%20A%20Pooled%20Analysis%20of%20Three%20Phase%20IIIb%20Studies&amp;author=A.%20Passaro&amp;author=F.%20de%20Marinis&amp;author=H.Y.%20Tu&amp;author=K.K.%20Laktionov&amp;author=J.%20Feng&amp;volume=11&amp;publication_year=2021&amp;pages=709877&amp;pmid=34307179&amp;doi=10.3389/fonc.2021.709877&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-curroncol-32-00201">
<span class="label">24.</span><cite>Godin-Heymann N., Ulkus L., Brannigan B.W., McDermott U., Lamb J., Maheswaran S., Settleman J., Haber D.A. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 2008;7:874–879. doi: 10.1158/1535-7163.MCT-07-2387.</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-07-2387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18413800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer%20Ther.&amp;title=The%20T790M%20%E2%80%9Cgatekeeper%E2%80%9D%20mutation%20in%20EGFR%20mediates%20resistance%20to%20low%20concentrations%20of%20an%20irreversible%20EGFR%20inhibitor&amp;author=N.%20Godin-Heymann&amp;author=L.%20Ulkus&amp;author=B.W.%20Brannigan&amp;author=U.%20McDermott&amp;author=J.%20Lamb&amp;volume=7&amp;publication_year=2008&amp;pages=874-879&amp;pmid=18413800&amp;doi=10.1158/1535-7163.MCT-07-2387&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-curroncol-32-00201">
<span class="label">25.</span><cite>Thress K.S., Paweletz C.P., Felip E., Cho B.C., Stetson D., Dougherty B., Lai Z., Markovets A., Vivancos A., Kuang Y., et al.  Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015;21:560–562. doi: 10.1038/nm.3854.</cite> [<a href="https://doi.org/10.1038/nm.3854" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4771182/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25939061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=Acquired%20EGFR%20C797S%20mutation%20mediates%20resistance%20to%20AZD9291%20in%20non-small%20cell%20lung%20cancer%20harboring%20EGFR%20T790M&amp;author=K.S.%20Thress&amp;author=C.P.%20Paweletz&amp;author=E.%20Felip&amp;author=B.C.%20Cho&amp;author=D.%20Stetson&amp;volume=21&amp;publication_year=2015&amp;pages=560-562&amp;pmid=25939061&amp;doi=10.1038/nm.3854&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-curroncol-32-00201">
<span class="label">26.</span><cite>Rangachari D., To C., Shpilsky J.E., VanderLaan P.A., Kobayashi S.S., Mushajiang M., Lau C.J., Paweletz C.P., Oxnard G.R., Jänne P.A., et al.  EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J. Thorac. Oncol. 2019;14:1995–2002. doi: 10.1016/j.jtho.2019.07.016.</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.07.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6823139/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31377341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=EGFR-Mutated%20Lung%20Cancers%20Resistant%20to%20Osimertinib%20through%20EGFR%20C797S%20Respond%20to%20First-Generation%20Reversible%20EGFR%20Inhibitors%20but%20Eventually%20Acquire%20EGFR%20T790M/C797S%20in%20Preclinical%20Models%20and%20Clinical%20Samples&amp;author=D.%20Rangachari&amp;author=C.%20To&amp;author=J.E.%20Shpilsky&amp;author=P.A.%20VanderLaan&amp;author=S.S.%20Kobayashi&amp;volume=14&amp;publication_year=2019&amp;pages=1995-2002&amp;pmid=31377341&amp;doi=10.1016/j.jtho.2019.07.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-curroncol-32-00201">
<span class="label">27.</span><cite>Naumov G.N., Nilsson M.B., Cascone T., Briggs A., Straume O., Akslen L.A., Lifshits E., Byers L.A., Xu L., Wu H.K., et al.  Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 2009;15:3484–3494. doi: 10.1158/1078-0432.CCR-08-2904.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-08-2904" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2893040/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19447865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Combined%20vascular%20endothelial%20growth%20factor%20receptor%20and%20epidermal%20growth%20factor%20receptor%20(EGFR)%20blockade%20inhibits%20tumor%20growth%20in%20xenograft%20models%20of%20EGFR%20inhibitor%20resistance&amp;author=G.N.%20Naumov&amp;author=M.B.%20Nilsson&amp;author=T.%20Cascone&amp;author=A.%20Briggs&amp;author=O.%20Straume&amp;volume=15&amp;publication_year=2009&amp;pages=3484-3494&amp;pmid=19447865&amp;doi=10.1158/1078-0432.CCR-08-2904&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-curroncol-32-00201">
<span class="label">28.</span><cite>Seiwerth F., Bitar L., Samaržija M., Jakopović M. Long-term progression-free survival in non-small cell lung cancer patients: A spotlight on bevacizumab and its biosimilars. Expert Opin. Biol. Ther. 2024;24:1017–1024. doi: 10.1080/14712598.2024.2405562.</cite> [<a href="https://doi.org/10.1080/14712598.2024.2405562" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39285584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin.%20Biol.%20Ther.&amp;title=Long-term%20progression-free%20survival%20in%20non-small%20cell%20lung%20cancer%20patients:%20A%20spotlight%20on%20bevacizumab%20and%20its%20biosimilars&amp;author=F.%20Seiwerth&amp;author=L.%20Bitar&amp;author=M.%20Samar%C5%BEija&amp;author=M.%20Jakopovi%C4%87&amp;volume=24&amp;publication_year=2024&amp;pages=1017-1024&amp;pmid=39285584&amp;doi=10.1080/14712598.2024.2405562&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-curroncol-32-00201">
<span class="label">29.</span><cite>Planchard D., Loriot Y., André F., Gobert A., Auger N., Lacroix L., Soria J.C. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 2015;26:2073–2078. doi: 10.1093/annonc/mdv319.</cite> [<a href="https://doi.org/10.1093/annonc/mdv319" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26269204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=EGFR-independent%20mechanisms%20of%20acquired%20resistance%20to%20AZD9291%20in%20EGFR%20T790M-positive%20NSCLC%20patients&amp;author=D.%20Planchard&amp;author=Y.%20Loriot&amp;author=F.%20Andr%C3%A9&amp;author=A.%20Gobert&amp;author=N.%20Auger&amp;volume=26&amp;publication_year=2015&amp;pages=2073-2078&amp;pmid=26269204&amp;doi=10.1093/annonc/mdv319&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-curroncol-32-00201">
<span class="label">30.</span><cite>Zhang Y., Zeng L., Zhang X., Li Y., Liu L., Xu Q., Yang H., Jiang W., Lizaso A., Qiu L., et al.  Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Med. 2021;19:245.  doi: 10.1186/s12916-021-02118-x.</cite> [<a href="https://doi.org/10.1186/s12916-021-02118-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8525046/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34663309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med.&amp;title=Clinical%20and%20molecular%20feature-based%20nomogram%20model%20for%20predicting%20benefit%20from%20bevacizumab%20combined%20with%20first-generation%20EGFR-tyrosine%20kinase%20inhibitor%20(TKI)%20in%20EGFR-mutant%20advanced%20NSCLC&amp;author=Y.%20Zhang&amp;author=L.%20Zeng&amp;author=X.%20Zhang&amp;author=Y.%20Li&amp;author=L.%20Liu&amp;volume=19&amp;publication_year=2021&amp;pages=245&amp;pmid=34663309&amp;doi=10.1186/s12916-021-02118-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-curroncol-32-00201">
<span class="label">31.</span><cite>Yu Y., Wang Y., Wu L., Xu X., Zhou H., Wang Q., Zhou J. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. Medicine. 2021;100:e23712. doi: 10.1097/MD.0000000000023712.</cite> [<a href="https://doi.org/10.1097/MD.0000000000023712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7870213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33592829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Efficacy%20of%20epidermal%20growth%20factor%20receptor%20tyrosine%20kinase%20inhibitors%20(EGFR-TKIs)%20combined%20with%20bevacizumab%20for%20advanced%20non-squamous%20non-small-cell%20lung%20cancer%20patients%20with%20gradual%20progression%20on%20EGFR-TKI%20treatment:%20A%20cohort%20study&amp;author=Y.%20Yu&amp;author=Y.%20Wang&amp;author=L.%20Wu&amp;author=X.%20Xu&amp;author=H.%20Zhou&amp;volume=100&amp;publication_year=2021&amp;pages=e23712&amp;pmid=33592829&amp;doi=10.1097/MD.0000000000023712&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-curroncol-32-00201">
<span class="label">32.</span><cite>Park K., Tan E.H., O’Byrne K., Zhang L., Boyer M., Mok T., Hirsh V., Yang J.C., Lee K.H., Lu S., et al.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589. doi: 10.1016/S1470-2045(16)30033-X.</cite> [<a href="https://doi.org/10.1016/S1470-2045(16)30033-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27083334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=Afatinib%20versus%20gefitinib%20as%20first-line%20treatment%20of%20patients%20with%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20(LUX-Lung%207):%20A%20phase%202B,%20open-label,%20randomised%20controlled%20trial&amp;author=K.%20Park&amp;author=E.H.%20Tan&amp;author=K.%20O%E2%80%99Byrne&amp;author=L.%20Zhang&amp;author=M.%20Boyer&amp;volume=17&amp;publication_year=2016&amp;pages=577-589&amp;pmid=27083334&amp;doi=10.1016/S1470-2045(16)30033-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-curroncol-32-00201">
<span class="label">33.</span><cite>Hirsh V. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clin. Lung Cancer. 2008;9((Suppl. S2)):S62–S70. doi: 10.3816/CLC.2008.s.010.</cite> [<a href="https://doi.org/10.3816/CLC.2008.s.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21885001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Emerging%20safety%20data%20for%20bevacizumab%20in%20advanced%20non-small-cell%20lung%20cancer&amp;author=V.%20Hirsh&amp;volume=9&amp;issue=(Suppl.%20S2)&amp;publication_year=2008&amp;pages=S62-S70&amp;pmid=21885001&amp;doi=10.3816/CLC.2008.s.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-curroncol-32-00201">
<span class="label">34.</span><cite>Ichihara E., Hotta K., Nogami N., Kuyama S., Kishino D., Fujii M., Kozuki T., Tabata M., Harada D., Chikamori K., et al.  Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group Trial 1001. J. Thorac. Oncol. 2015;10:486–491. doi: 10.1097/JTO.0000000000000434.</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25695221/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Phase%20II%20trial%20of%20gefitinib%20in%20combination%20with%20bevacizumab%20as%20first-line%20therapy%20for%20advanced%20non-small%20cell%20lung%20cancer%20with%20activating%20EGFR%20gene%20mutations:%20The%20Okayama%20Lung%20Cancer%20Study%20Group%20Trial%201001&amp;author=E.%20Ichihara&amp;author=K.%20Hotta&amp;author=N.%20Nogami&amp;author=S.%20Kuyama&amp;author=D.%20Kishino&amp;volume=10&amp;publication_year=2015&amp;pages=486-491&amp;pmid=25695221&amp;doi=10.1097/JTO.0000000000000434&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-curroncol-32-00201">
<span class="label">35.</span><cite>Elamin Y.Y., Nagasaka M., Shum E., Bazhenova L., Camidge D.R., Cho B.C., Felip E., Goto K., Lin C.-C., Piotrowska Z., et al.  BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study. J. Clin. Oncol. 2023;41:9011.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=BLU-945%20monotherapy%20and%20in%20combination%20with%20osimertinib%20(OSI)%20in%20previously%20treated%20patients%20with%20advanced%20EGFR-mutant%20(EGFRm)%20NSCLC%20in%20the%20phase%201/2%20SYMPHONY%20study&amp;author=Y.Y.%20Elamin&amp;author=M.%20Nagasaka&amp;author=E.%20Shum&amp;author=L.%20Bazhenova&amp;author=D.R.%20Camidge&amp;volume=41&amp;publication_year=2023&amp;pages=9011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-curroncol-32-00201">
<span class="label">36.</span><cite>Eno M.S., Brubaker J.D., Campbell J.E., De Savi C., Guzi T.J., Williams B.D., Wilson D., Wilson K., Brooijmans N., Kim J., et al.  Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J. Med. Chem. 2022;65:9662–9677. doi: 10.1021/acs.jmedchem.2c00704.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.2c00704" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9340769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35838760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Discovery%20of%20BLU-945,%20a%20Reversible,%20Potent,%20and%20Wild-Type-Sparing%20Next-Generation%20EGFR%20Mutant%20Inhibitor%20for%20Treatment-Resistant%20Non-Small-Cell%20Lung%20Cancer&amp;author=M.S.%20Eno&amp;author=J.D.%20Brubaker&amp;author=J.E.%20Campbell&amp;author=C.%20De%20Savi&amp;author=T.J.%20Guzi&amp;volume=65&amp;publication_year=2022&amp;pages=9662-9677&amp;pmid=35838760&amp;doi=10.1021/acs.jmedchem.2c00704&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-curroncol-32-00201">
<span class="label">37.</span><cite>Jia Y., Yun C.H., Park E., Ercan D., Manuia M., Juarez J., Xu C., Rhee K., Chen T., Zhang H., et al.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129–132. doi: 10.1038/nature17960.</cite> [<a href="https://doi.org/10.1038/nature17960" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4929832/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27251290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Overcoming%20EGFR(T790M)%20and%20EGFR(C797S)%20resistance%20with%20mutant-selective%20allosteric%20inhibitors&amp;author=Y.%20Jia&amp;author=C.H.%20Yun&amp;author=E.%20Park&amp;author=D.%20Ercan&amp;author=M.%20Manuia&amp;volume=534&amp;publication_year=2016&amp;pages=129-132&amp;pmid=27251290&amp;doi=10.1038/nature17960&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-curroncol-32-00201">
<span class="label">38.</span><cite>Wang S., Song Y., Liu D. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51–54. doi: 10.1016/j.canlet.2016.11.008.</cite> [<a href="https://doi.org/10.1016/j.canlet.2016.11.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27840244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett.&amp;title=EAI045:%20The%20fourth-generation%20EGFR%20inhibitor%20overcoming%20T790M%20and%20C797S%20resistance&amp;author=S.%20Wang&amp;author=Y.%20Song&amp;author=D.%20Liu&amp;volume=385&amp;publication_year=2017&amp;pages=51-54&amp;pmid=27840244&amp;doi=10.1016/j.canlet.2016.11.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-curroncol-32-00201">
<span class="label">39.</span><cite>Wen P.Y., Johnson M.L., Henry J.T., Spira A., Battiste J., Alnahhas I., Nam D.-H., Patel J.D., Edenfield W.J., Hormigo A., et al.  Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results. J. Clin. Oncol. 2024;42:2068.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Phase%201%20study%20of%20BDTX-1535,%20an%20oral%204th%20generation%20covalent%20EGFR%20inhibitor,%20in%20patients%20with%20recurrent%20glioblastoma:%20Preliminary%20dose%20escalation%20results&amp;author=P.Y.%20Wen&amp;author=M.L.%20Johnson&amp;author=J.T.%20Henry&amp;author=A.%20Spira&amp;author=J.%20Battiste&amp;volume=42&amp;publication_year=2024&amp;pages=2068&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-curroncol-32-00201">
<span class="label">40.</span><cite>Patel J., Spira A., Stevenson J., Chen H., Baik C., Gordon S., Henry J.T., Ahluwalia M., Barve M., Huang C., et al.  EP.12H.01 A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2024;19:S657.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=EP.12H.01%20A%20Phase%202%20Study%20to%20Assess%20BDTX-1535,%20An%20Oral%20EGFR%20Inhibitor,%20in%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer&amp;author=J.%20Patel&amp;author=A.%20Spira&amp;author=J.%20Stevenson&amp;author=H.%20Chen&amp;author=C.%20Baik&amp;volume=19&amp;publication_year=2024&amp;pages=S657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data underlying the findings of this study are available within this publication. Patient data from the West China Hospital in Sichuan University have been anonymized to ensure confidentiality. Due to ethical and legal restrictions related to data protection regulations, raw patient data cannot be shared publicly. Requests for further information may be directed to the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Current Oncology are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/curroncol32040201"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/curroncol-32-00201.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (992.9 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12025375/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12025375/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12025375%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12025375/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12025375/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12025375/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40277759/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12025375/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40277759/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12025375/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12025375/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="soSpvNYmrmx8CmTxhXvtqurYEnA9gSJ35UF614ePgiwcQ6DXB8aB7rIcolWqmAk7">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
